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ABSTRACT: The synthesis of the Securinega alkaloid secu’amamine E (ent–virosine A) has been accomplished for the first time in 12 steps 
and 8.5% overall yield. In addition, bubbialine has been prepared and characterized. These two alkaloids and bubbialidine, all featuring an 
azabicyclo[2.2.2]octane core, were rearranged to their azabicyclo[3.2.1]octane congeners, a framework found in many Securinega alkaloids. 
These experiments suggest that azabicyclo[2.2.2]octane derivatives could serve as intermediates in the biosynthesis of the rearranged azabi-
cyclo[3.2.1]octane products. 
The Securinega alkaloids consist of a group of more than 60 
known secondary metabolites isolated from plants of several genera 
of the Phyllanthaceae family, including Securinega, Phyllanthus, 
Flueggea and others.1 Some of these plants have been used in tradi-
tional folk medicines across Asia, Africa and Amazonia, and subse-
quently, several compounds of the family were shown to exhibit 
antimalarial, antibacterial, antitumor as well as central nerve system 
activities.1,2 Among the Securinega alkaloids, securinine constitutes 
the most abundant and best-studied representative featuring the 
securinane skeleton (Scheme 1A), and the group includes a series 
of isomeric neosecurinane-type and two lower homologs of norse-
curinane- and neonorsecurinane-type, respectively (see Scheme 1A 
for an overview). Structurally, these compounds can be divided in 
groups featuring either azabicyclo[2.2.2]- or azabicy-
clo[3.2.1]octane BC ring systems with a fused pyrrolidine or piper-
idine ring. Their interesting biological activities combined with the 
bridged tetracyclic core structure triggered numerous synthetic 
efforts toward Securinega alkaloids.1,2c,3,4 
Secu'amamine E (1) was isolated along with two new congeners 
from Securinega suffruticosa var. amamiensis by Ohsaki et al. in 20095 
and constitutes a member of the neosecurinane series. The enanti-
omer ent-1 has also been isolated as virosine A from Flueggea vi-
rosa,6 although this relationship was not revealed in the subse-
quent.5 The lower homolog of 1, bubbialidine (2), the synthesis of 
which we have reported recently,7 belongs to the neonorsecurinane 
family and was isolated along with the isomeric bubbialine (3).8 
While allosecurinine (4) is a natural epimer of securinine, neither 
enantiomer of allonorsecurinine (5) has been obtained from a 
natural source, in contrast to securinol A (6) and viroallosecurinine 
(7).9 
The biosynthetic origin of both the A ring and the C/D system 
has been investigated over decades,10 and can be traced back to 
lysine and tyrosine catabolites, which merge to the postulated 
tricyclic intermediate 8 (Scheme 1B). The origin of the B/C bicy-
clic ring system however, received much less attention, and there-
fore remains an interesting subject for scientific investigation. The 
general biosynthetic pathway formulated in the 1970s suggested 
that intermediate 8 can either react via reduction and 1,6-addition 
to the azabicyclo[2.2.2]octane system to form e.g. 1, or via reduc-
tion and amination to the azabicyclo[3.2.1]octane system to direct-
ly afford 4.10 An alternative biogenetic hypothesis suggests that 
compounds featuring the azabicyclo[2.2.2]octane ring system 1 
could be intermediates, of which the azabicyclo[3.2.1]octane com-
pounds of type 4 would result through subsequent rearrangement 
involving an aziridinium ion such as 9, which has already been 
postulated by Horii et al. in the 1960s.11 This hypothesis has, to the 
best of our knowledge, first been suggested by Magnus et al. in 
1993,12 but later received little attention,4g and recent review articles 
do not mention this mechanistic possibility. 
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Scheme 1. General structures and biogenetic hypotheses of 
Securinega alkaloids. 
  
In this study, we provide experimental evidence for the second 
hypothesis by converting three different azabicyclo[2.2.2] natural 
products to the rearranged azabicyclo[3.2.1] congeners. Along 
these lines, the first total syntheses of secu’amamine E/ent-virosine 
A (1) and bubbialine (3) are reported. 
Analogous to our earlier work,7 the key intermediate in our syn-
thesis of secu’amamine E (1) is TBDPS-protected 
(+)-aquilegiolide (10), for which a shorter synthesis was developed 
(Scheme 2). Ketal 11 was transformed into enone 12 in four steps 
and 37% overall yield following procedures developed by Hayashi 
et al. during their total synthesis of (+)-panepophenanthrin.13 To 
this goal, a proline-catalyzed stereoselective a-addition of nitro-
sobenzene, a reduction of the ketone using K-selectride followed by 
reductive N-O cleavage and finally an acid-catalyzed ketal hydroly-
sis with concomitant elimination of water led to the desired 
g-hydroxy enone 12. The hydroxyl function was protected with a 
TBDPS group to give fully protected enone 13 in 94% yield. For 
the subsequent a-hydroxylation, we first investigated the use of 
Rubottom oxidation conditions.14 While 1H NMR analyses indicat-
ed clean formation of the corresponding silyl enol ethers using 
either TMSCl or TESCl and NaHMDS, the subsequent reaction 
with mCPBA led to decomposition of the substrate and complex 
mixtures were obtained. We then evaluated Davis' oxaziridines as 
oxidants and treatment of the pre-formed sodium enolate with 3-
phenyl-2-(phenylsulfonyl)oxaziridine (14)15 at –78 °C yielded 
a-hydroxy ketone 15. In addition, a clean formation of the product 
was also observed when a mixture of enone 13 and oxaziridine 14 
in THF at –78 °C was reacted with NaHMDS. However, isolation 
and purification turned out to be difficult, as enone 15 was not 
stable during flash column chromatography. Moreover, N-
benzylidenebenzenesulfonamide, the byproduct formed from 
oxaziridine 14, displayed very similar retention properties on silica 
as the hydroxy ketone 15. When instead (+)-(8,8-dichloro-
camphorylsulfonyl)oxaziridine was used to generate a different 
byproduct, none of the desired product 15 was detected. The best 
results were obtained by washing the organic fraction with aqueous 
NaHSO3, therefore removing most of the imine and aldehyde 
contents, and followed by filtration with apolar solvent to remove 
insoluble benzenesulfonamide. To setup the butenolide D ring, we 
applied an efficient one-pot addition/Wittig reaction sequence 
using the Bestmann ylide ((triphenylphosphoranylidene)ketene, 
16).16 a-Hydroxy enone 15 was heated in benzene in the presence 
of ketene 16 to give the bicyclic key intermediate 10 in 43% yield 
over two steps as a mixture of diastereoisomers (3.3:1), which was 
inconsequential and the isomers were this not separated. While 
lower temperatures only slowed down the reaction, the addition of 
triethylamine did not have any impact on yield. 
 
Scheme 2. Synthesis of bicyclic key intermediate 7 
   
The A ring was introduced using a one-pot procedure reported 
by Busqué, de March et al. producing the desired product 17 in 
high yield and good selectivity (Scheme 3).17 Since the reaction 
proceeds via silyl enol ether 18, both diastereoisomers of interme-
diate 10 lead to the same product. The two diastereoisomers gen-
erated could be separated by silica column chromatography. The 
Boc protecting group was then removed with ethereal HCl solution 
at elevated temperature to give the desired hydrochloride in 97% 
yield. When the salt was heated in a suspension of dipotassium 
phosphate in DMF the desired tetracycle 19 was isolated in varying 
yields. Applying more basic potassium carbonate in this transfor-
mation afforded silyl ether 19 in a yield of 81%. Final deprotection 
of the hydroxyl function by treatment with excess HF•pyridine 
afforded secu'amamine E (1) in 98% yield. Thus, the neose-
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curinane alkaloid 1 was synthesized in 12 steps in an overall yield of 
8.5%. All analytical data obtained from the synthetic material were 
identical with those reported for the authentic natural product. The 
optical rotation of –45.7° (c = 0.10, MeOH) of the synthetic alka-
loid 1 matched the value of –43.8° (c = 0.08, MeOH) reported by 
Ohsaki et al.5 
 
Scheme 3. Enantioselective synthesis of secu'amamine E 
  
In order to profile the ecotoxicity of this alkaloid, we tested the 
synthetic material for toxicity against the freshwater crustacean 
Thamnocephalus platyurus (beavertail fairy shrimp).18 In an acute 
toxicity assay, five concentrations of alkaloid 1 ranging from 1.23 
µM to 100 µM were incubated with 10 animals for 24 h, each con-
centration in three separate experiments. Each experiment was 
evaluated by visual inspection of the animals before and after incu-
bation. However, no toxicity of alkaloid 1 could be observed in this 
concentration range. In addition to secu’amamine E (1), we have 
obtained bubbialidine (2) and bubbialine (3) following a previous-
ly published route.7 In this context, bubbialine (3) was character-
ized for the first time during this work. 
We then focused on evaluating the feasibility of the hypothesis 
outlined above, i.e. if the azabicyclo[2.2.2]octane ring system 1 
constitutes an intermediate en route to azabicyclo[3.2.1]octane 
compounds of type 4. To test the generality of the dehydrative 
rearrangement outlined above in Scheme 1B, we treated synthetic 
samples of secu'amamine E (1), bubbialidine (2) and bubbialine 
(3) with MsCl in the presence of DMAP and Et3N. Alkaloids 1 and 
2 reacted within seconds at room temperature to give the rear-
ranged alkaloids allosecurinine (4) and (–)-allonorsecurinine ((–)-
5), respectively, in up to 93% yield (Scheme 4A and B). In contrast, 
bubbialine (3) reacted to give the corresponding mesylate 20 
under these conditions, which could be isolated and purified by 
chromatography on silica gel (Scheme 4C). To effect the rear-
rangement of the sulfonate 20, forcing conditions had to be applied 
(100 °C, microwave, 6 h) and (+)-allonorsecurinine ((+)-5) was 
isolated in low yield and moderate purity. These experimental 
observations can be explained by the mechanistic rationale outlined 
in Scheme 4. Formation of the aziridinium intermediates 9 or 21 is 
highly favored for alkaloids with an antiperiplanar configuration of 
the amino and hydroxy groups on the C ring, as the nitrogen is well 
aligned to donate electron density into the s* orbital of the exocy-
clic C-O bond. Thus, the structure allows for rapid extrusion of the 
mesylate via such a mechanism. However, when the groups are 
arranged in synperiplanar configuration, such as for 5, this orbital 
interaction is less feasible and the mesylate has to leave in an SN1 
fashion. 
 
Scheme 4. Dehydrative rearrangement of Securinega alkaloids 
 
As a consequence of these mechanistic observations, we specu-
late that neosecurinane- and neonorsecurinane-type alkaloids 
possessing a [2.2.2]-bicyclic core serve as direct biosynthetic in-
termediates of securinane- and norsecurinane-type alkaloids with 
an unsaturated [3.2.1] core. Accordingly, the biosynthesis of 
a,b,g,d-unsaturated Securinega alkaloids would be extended by an 
additional intermediate featuring an OH group and thus follow a 
linear pathway (Scheme 1B). Based on the hypothesis by Busqué, 
de March et al., intermediate 8 may also be formulated as an alco-
hol instead of the ketone.17 Analogous to the transformation of 10 
reported in Scheme 3, the tricyclic amine might derive naturally 
from the bicyclic lactones (+)-aquilegiolide and/or (+)-
menisdaurilide via vinylogous Mannich reaction and thus already 
contain the hydroxy group. 
In summary, we have completed the first enantioselective total 
synthesis of secu’amamine E (1) in 12 steps and 8.5% overall yield. 
Key transformations are a butenolide formation using the Best-
mann ylide (16), a vinylogous Mannich reaction to introduce the A 
ring and an intramolecular aza-Michael addition to form the B ring. 
Furthermore, three synthetic natural products (1, 2 and 3) featur-
ing an azabicyclo[2.2.2]octane core were rearranged to their azabi-
cyclo[3.2.1]octane congeners supporting a linear biogenetic hy-
pothesis for Securinega alkaloids. Thus, neo(nor)securinane-type 
alkaloids with an antiperiplanar configuration on the C ring might 
serve as natural precursors of the (nor)securinane-type alkaloids. 
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Detailed experimental procedures, analytical data and NMR spectra 
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